The successful refinancing and enhancement of the syndicated credit facilities provides access to an additional CHF 40 million
FIBROSARC did not meet its primary PFS endpoint in the final analysi
New funding to advance non-surgical brain interface technology and expand clinical and engineering capabilities globally
Agreements mark a major victory in the President’s long-term pledge to lower prescription drug costs for Americans
The results demonstrated meaningful reductions in the severity of involuntary movements and notable improvements in patient-reported quality of life
While the trial fell short of demonstrating a statistically significant PFS benefit compared to chemotherapy, early data suggest a potential overall survival advantage
The offering is expected to close on November 10, 2025, subject to customary closing conditions
Poviztra is a second brand of Wegovy
Syngene International has reported total income of Rs. 926 crore during the period ended September 30, 2025
The discussions come as part of the administration’s broader efforts to drive down drug prices and increase patient access to essential therapies
Subscribe To Our Newsletter & Stay Updated
